Omega-3 (EPA/DHA) evidence, 2019
Bhatt DL, Steg PG, Miller M, et al., New England Journal of Medicine, 2019 — REDUCE-IT trial of icosapent ethyl 4 g/day
- Grade
- Design
- rct
- Year
- 2019
- Participants
- 8179
- Ingredient
- Omega-3 (EPA/DHA)
- Goal
- Heart & metabolic
Effect
Prescription-grade EPA at 4 g/day reduced major cardiovascular events versus placebo in statin-treated adults with elevated triglycerides.
Limitations and notes
Graded B for our context: a prescription EPA ester in a selected population — supportive but not directly transferable to over-the-counter fish oil.